Guobang Pharma Ltd

Zhejiang Guobang Pharmaceutical, a wholly owned subsidiary of Guobang Pharma, has been fined and had 255,000 yuan confiscated by the Shaoxing Emergency Management Bureau after 12 safety problems were identified. According to administrative penalty information disclosed on the Credit China Zhejiang website, law enforcement officers from the Shaoxing Emergency Management Bureau carried out an inspection of Zhejiang Guobang Pharmaceutical on May 21, 2026, under the annual enforcement plan. Problems found included failure to establish a registration system for checking hazardous chemicals in and out of storage, failure to insure all employees under work safety liability insurance, lack of splash protection at multiple pipeline flange connections, failure to post warning signs in confined spaces, failure to install static discharge devices and hydrogen leak alarms in the high-purity hydrogen warehouse, malfunctioning of some level gauges and online oxygen content detectors, and one outside operator at the hydrogenation post working without a special operations certificate. On September 7, the Shaoxing Emergency Management Bureau imposed the above administrative penalty on Zhejiang Guobang Pharmaceutical. Guobang Pharma's semi-annual report shows that Zhejiang Guobang Pharmaceutical is an important wholly owned subsidiary mainly engaged in the production and sale of pharmaceutical active ingredients, with operating revenue of 1.399 billion yuan and net profit of 139 million yuan in the first half of 2026.

Guobang Pharma released its 2026 interim report, with net profit attributable to the parent company at 341 million yuan, a decrease of 25.07% compared to the same period last year. Total operating revenue was 3.142 billion yuan, up 3.84% year-on-year, marking five consecutive years of growth. Net cash inflow from operating activities was 455 million yuan, a substantial increase of 342.23% year-on-year. The company's latest gross margin was 23.77%, down 3.08 percentage points from the same period last year, and ROE was 4.06%, down 1.59 percentage points.